Upgrade to SI Premium - Free Trial

Teva Pharma (TEVA) Announces NEJM Publishes Data from Pivotal Phase III Trial of Fremanezumab for Preventive Treatment of Chronic Migraine

November 29, 2017 5:07 PM
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the publication of data from the pivotal Phase III HALO ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles